Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TERT | O14746 | 1/20 | 0.46 |
| ▸ | BACE1 | P56817 | 4/20 | 0.45 |
| ▸ | BCHE | P06276 | 4/20 | 0.44 |
| ▸ | VSIR | Q9H7M9 | 2/20 | 0.44 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.43 |
| ▸ | CTSD | P07339 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | EGFR | P00533 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.38 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10077679 | 0.82 | BACE1 (0.48) | BACE1BCHECTSDL3MBTL1CHRM2 | |
| SCHEMBL18542697 | 0.81 | MC4R (0.54) | BACE1BCHEVSIRCTSDL3MBTL1 | |
| SCHEMBL13999438 | 0.81 | BACE1 (0.50) | BACE1BCHECTSDSMN1; SMN2L3MBTL1 | |
| SCHEMBL11983543 | 0.79 | TERT (0.49) | TERTVSIRMAP4K4SMN1; SMN2KDM4E | |
| SCHEMBL13675373 | 0.79 | TERT (0.49) | TERTVSIRMAP4K4SMN1; SMN2CHRM2 | |
| SCHEMBL19523060 | 0.78 | BCHE (0.49) | BACE1BCHECTSDSMN1; SMN2KDM4E | |
| SCHEMBL10053248 | 0.78 | TAAR1 (0.58) | SMN1; SMN2KDM4EALDH1A1LMNA | |
| SCHEMBL12956598 | 0.78 | BCHE (0.56) | BACE1BCHECTSDSMN1; SMN2KDM4E | |
| SCHEMBL19121876 | 0.78 | BACE1 (0.48) | BACE1BCHECTSDL3MBTL1CHRM2 | |
| SCHEMBL22882317 | 0.78 | MC4R (0.56) | BACE1BCHECTSDCHRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10316017-B2 | COT modulators and methods of use thereof | GILEAD SCIENCES, INC. (US) | 2019-06-11 | — | — | US | disclosed |
| US-20170362201-A1 | COT MODULATORS AND METHODS OF USE THEREOF | GILEAD SCIENCES, INC. | 2017-12-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170362201-A1 | COT MODULATORS AND METHODS OF USE THEREOF | BRDT, THRB, HCCS | TERT 300/4885BACE1 4825/4885BCHE 2563/4885 |
| US-10316017-B2 | COT modulators and methods of use thereof | BRDT, THRB, HCCS | TERT 300/4885BACE1 4825/4885BCHE 2563/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.